Pearl Bio
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.0Mattributed |
|---|---|
| Latest round | series-a, $1.0M, 2024-01-01attributed |
| Founded | 2020 |
| Headquarters | Washington, DC |
| Industry | medtech |
| Stage | series-a |
| Website | pearlbio.com |
Pearl Bio uses genome and ribosome engineering to manufacture biologics with non-canonical amino acids and novel chemistries. It serves pharma partners looking for protein-drug formats outside what natural ribosomes can build. A $1B collaboration with Merck for engineered cancer biologics is the kind of platform deal narrow-spectrum protein-engineering shops rarely attract.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | series-a | $1.0M | khosla |
Detected tech stack
Cloudflare, All in One SEO 4.4.3, All in One SEO Pack 4.4.3, Kinsta, Google Analytics, Google Tag Manager, Font Awesome, jQuery Migrate 3.4.1, Elementor 3.13.4, Elementor Addon Elements 1.1.0, particles.js, DoubleClick Floodlight
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $1.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Total raised $1.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Company existence | self-reported | pearlbio.com, read 2026-05-07 |
| Description | self-reported | pearlbio.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.